Form D · Biotechnology
Nitric BioTherapeutics, Inc.
Bristol, PA · CIK 0001460586
Offering snapshot reported Jan 20, 2012 · SEC filing
- Reported sold
- $1.02M Offering amount: $1.25M
- Investors reported
- 4 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jan 9, 2012 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 20, 2012 | Initial | $1,020,000 | No comparison | 4 | SEC filing |
| Nov 29, 2011 | Initial | $1,000,000 | No comparison | 1 | SEC filing |
| Jul 12, 2010 | Initial | $1,750,000 | No comparison | 6 | SEC filing |
| Apr 3, 2009 | Initial | $1,688,739 | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Debt
- Exemptions
- 05, 06
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-172232
Source: Form D, filed Jan 20, 2012. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Al Altomari | Director |
| Richard Caruso | Director |
| Harold Chefitz | Director |
| Brian M. Gallagher | Director |
| Hugh Mac Naught | Director |
| Frank J. Mc Caney | Director, Executive |
| Jeffrey O'donnell | Director |
| Adele Oliva | Director |
| James Ratigan | Executive |
| Matthew Rieke | Director |
| Marcus Schabacker | Director |
| Zev Scherl | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
2 Canal's End Road
Bristol, PA, 19007
Bristol, PA, 19007